Spyre says bowel disease drug cuts inflammation in mid-stage trial
Spyre Therapeutics(US:SYRE) Reuters·2026-06-15 20:28公司研发进展 - Spyre Therapeutics的实验性肠道疾病药物在中期试验中达到了主要目标，即显著降低疾病严重程度 [1]
Spyre Therapeutics(US:SYRE) Reuters·2026-06-15 20:28Spyre Therapeutics(US:SYRE) Reuters·2026-06-15 20:28